BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19819538)

  • 1. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
    Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
    Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
    Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
    Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
    Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
    BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
    Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
    J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment.
    Scarpa RM; Cracco CM
    Urology; 2009 Dec; 74(6):1286-7; author reply 1287-8. PubMed ID: 19962530
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].
    Danil'chenko DI; Koenig F; Riedl K; Schnorr D; Waldman A; Al-Shukri S; Loening SA
    Vopr Onkol; 2003; 49(6):734-7. PubMed ID: 14976918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
    Schumacher MC; Holmäng S; Davidsson T; Friedrich B; Pedersen J; Wiklund NP
    Eur Urol; 2010 Feb; 57(2):293-9. PubMed ID: 19913351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
    Burger M; Zaak D; Stief CG; Filbeck T; Wieland WF; Roessler W; Denzinger S
    Eur Urol; 2007 Jul; 52(1):142-7. PubMed ID: 17267099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
    BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of the photodynamic method in the diagnosis of superficial bladder tumors].
    Lipiński MI; Jeromin LM
    Wiad Lek; 2004; 57 Suppl 1():192-5. PubMed ID: 15884237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
    Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D
    Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group].
    Burgués JP; Conde G; Oliva J; Abascal JM; Iborra I; Puertas M; Ordoño F;
    Actas Urol Esp; 2011 Sep; 35(8):439-45. PubMed ID: 21621301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of fluorescent control in raising radicality of surgical treatment for superficial bladder cancer].
    Matveev BP; Kudashev BV; Bukharkin BV; Romanov VA; Rubanov IuV
    Urologiia; 2000; (3):22-4. PubMed ID: 11186703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer.
    Inoue K; Fukuhara H; Shimamoto T; Kamada M; Iiyama T; Miyamura M; Kurabayashi A; Furihata M; Tanimura M; Watanabe H; Shuin T
    Cancer; 2012 Feb; 118(4):1062-74. PubMed ID: 21773973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
    Witjes JA; Douglass J
    Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.
    Todenhöfer T; Maas M; Ketz M; Kossack N; Colling C; Qvick B; Stenzl A
    World J Urol; 2021 Aug; 39(8):2953-2960. PubMed ID: 33569642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
    Witjes JA; Redorta JP; Jacqmin D; Sofras F; Malmström PU; Riedl C; Jocham D; Conti G; Montorsi F; Arentsen HC; Zaak D; Mostafid AH; Babjuk M
    Eur Urol; 2010 Apr; 57(4):607-14. PubMed ID: 20116164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
    Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
    BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.